Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STATLiver Trial: Atorvastatin for prevention of disease progression and hospitalization in liver cirrhosis
2019-001806-40Phase 2Terminated
- Sponsor
- Afsnit 360
- Start
- May 2019
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Lipistad in Cirrhosis (2 arms), sponsored by Afsnit 360. Primary endpoints: Composite endpoint of death or liver transplantation at 1.5 years and Composite endpoint of death or liver transplantation at 5 years. Started May 2019; status: terminated.
02
Drugs
Lipistad
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on 2019-001806-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001806-40.